頁籤選單縮合
題名 | Linezolid於多重抗藥性結核病治療角色之探討=Using Linezolid in the Treatment of Multidrug-resistant Tuberculosis |
---|---|
作者 | 黃怡萍; | 書刊名 | 藥學雜誌 |
卷期 | 27:2=107 2011.06[民100.06] |
頁次 | 頁68-73 |
分類號 | 418.2219 |
關鍵詞 | 多重抗藥性結核病; 實證醫學; Linezolid; Multidrug-resistant tuberculosis; Evidence-based medicine; |
語文 | 中文(Chinese) |
中文摘要 | 有鑑於多重抗藥性結核病的盛行,臨床醫療人員莫不積極尋求有效治療的新藥,以增加有效治療藥物達 4種以上。目前世界衛生組織將治療結核病的現有藥物分為五類,其中 linezolid屬於曾報告有效,但臨床效果未定之第五類藥物。 Linezolid長期使用可能有貧血、周邊和視神經病變等副作用,且由於此藥昂貴,所以臨床使用經驗有限。根據文獻回顧並從實證醫學的角度, linezolid 600 mg QD可增加多重抗藥性結核病患者治療成功的機會,同時在不影響藥效的情況下減少副作用的發生。因此,當可用藥物不足時, linezolid可考慮作為治療多重抗藥性結核病的替代藥物。 |
英文摘要 | The prevalence of multidrug-resistant tuberculosis (MDR-TB) is increasing globally, many clinical medication researchers made much efforts seeking new effective drugs for MDR-TB, an MDR-TB regimen should consist of at least four drugs with either certain. Treatment options for MDR-TB are limited, and new, effective drugs are needed. The categories of anti-TB drugs are divided into 5 groups by World Health Organization. Linezolid belongs to the Group 5 drugs which are not recommended by WHO for routine use in MDR-TB treatment, because the efficacy is unclear. Because of the long dividing time of MDR-TB, the high cost of linezolid, and anemia, peripheral and optic neuropathy associated with its long-term use, limited clinical experience. From evidence-based medicine point of view, linezolid 600 mg QD added to an individualized multidrug regimen may improve the chance of bacteriological conversion, providing a better chance of treatment success in MDRTB cases. It is likely that the potential benefits of linezolid can be achieved using a lower dosage, which appeared to reduce the risk of side-effects. Therefore, linezolid at a dosage of 600 mg once daily could be considered as a substitute drug to the MDR-TB treatment regimen for patients when suitable and effective drugs are not enough. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。